ClinicalTrials.gg
CompletedNCT04772742SunlightUpdated Oct 31, 2022

Eptinezumab in Adults With Migraine and Medication Overuse Headache

A Phase 3 interventional study of Placebo and Eptinezumab in Migraine and Medication Overuse Headache, sponsored by H. Lundbeck A/S. Completed at 40 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-31.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
11th of 21
193 · median 193
Started
2021
with 4 others
Phase 3
13 of 21
5 open now
Registered
10th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 11th largest by enrollment, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 10th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache

Read the detailed description

Patients planned for randomization: 91 patients in the eptinezumab 100 mg group and 91 patients in the placebo group.

The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Open-Label Period (12 weeks) and a Safety Follow-up Period (8 weeks). Patient will receive investigational medicinal product (IMP) at the Baseline Visit with either eptinezumab or placebo by IV infusion and at week 12 visit.

03

Conditions studied

  • Migraine
  • Medication Overuse Headache
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 guidelines confirmed at the Screening Visit with a history of migraine onset of at least 12 months prior to the Screening Visit.
  • The patient has ≥8 migraine days per month for each month on average within the past 3 months prior to the Screening Visit.
  • The patient has a diagnosis of medication overuse headache (MOH) as defined by IHS ICHD-3 guidelines.
  • The patient has headache on ≥15 days/month for each month within the past 3 months prior to the Screening Visit.
  • The patient has regular overuse of one or more drugs that can be taken for acute and/or symptomatic treatment of headache, for >3 months.
  • The patient has ≥15 to ≤26 headache days, of which ≥8 days were assessed as migraine days during the Screening Period, based on prospectively collected information in the eDiary.
  • The patient overuses drugs that can be taken for acute and/or symptomatic treatment of headache during the Screening Period, based on prospectively collected information in the eDiary.
  • The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days of the Screening Period.
  • The patient has had an onset of migraine at \<50 years of age

Exclusion criteria

Exclusion Criteria:

  • The patient has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
  • The patient has confounding and pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • The patient has a diagnosis of acute or active temporomandibular disorder.
  • The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
  • Patients with a lifetime history of psychosis, bipolar mania, or dementia are excluded. Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded.
  • The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Double-Blind Treatment Phase (at baseline): Placebo by IV infusion Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion

    Drug: Placebo · Drug: Eptinezumab

Interventions

  • DrugPlacebo

    Placebo - solution for infusion

  • Eptinezumab - 100 mg, solution for infusion

    Also known as: Lu AG09221

06

What researchers measure

Primary outcomes

  1. Change from baseline in the number of monthly migraine days (MMDs)

    Time frame: Weeks 1-12

Secondary outcomes

  1. Change from baseline in MMDs with use of acute medication

    Time frame: Weeks 1-12

  2. Response: ≥50% reduction from baseline in MMDs

    Time frame: Weeks 1-12

  3. Migraine rate on the day after dosing

    Time frame: At Day 1

  4. Response: ≥75% reduction from baseline in MMDs

    Time frame: Weeks 1-4

  5. Change from baseline in the number of monthly headache days (MHDs)

    Time frame: Weeks 1-12

  6. Response: ≥75% reduction from baseline in MMDs

    Time frame: Weeks 1-12

  7. Response: ≥75% reduction from baseline in MHDs

    Time frame: Weeks 1-12

  8. Response: ≥75% reduction from baseline in MHDs

    Time frame: Weeks 1-4

  9. Change from baseline in the number of MHDs with use of acute medication

    Time frame: Weeks 1-12

  10. Change from baseline in rate of migraines with severe pain intensity

    Time frame: Weeks 1-12

  11. Change from baseline in rate of headaches with severe pain intensity

    Time frame: Weeks 1-12

  12. Patient Global Impression of Change (PGIC) score

    Time frame: At Week 12

  13. Most Bothersome Symptom (MBS) (score as measured relative to Screening)

    Time frame: At Week 12

  14. Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score

    Time frame: Baseline to Week 12

  15. Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)

    Time frame: Baseline to Week 12

  16. Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score

    Time frame: Baseline to Week 12

  17. Health Care Resources Utilization (HCRU)

    Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.

    Time frame: Baseline to Week 12

  18. Change from baseline to Week 12 in the Work Productivity and Activity impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)

    Time frame: Baseline to Week 12

07

Study locations

40 sites
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Beijing Chaoyang Hospital Capital Medical University
    Beijing, 100020, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, 100029, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
    Beijing, 610041, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • The Second Hospital of Jilin University
    Changchun, 130022, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, 400016, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, 550000, China
  • Mianyang Central Hospital
    Mianyang, 621000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, 337055, China
  • People's Hospital of Rizhao
    Rizhao, 276826, China
  • Shengjing Hospital of China Medical University
    Shenyang, 110004, China
  • General Hospital of Northern Theater Command
    Shenyang, 110015, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, 518053, China
  • Shanxi Provincial People Hospital
    Taiyuan, 030012, China
  • The 2nd Affiliated Hospital of Wenzhou Medical University
    Wenzhou, 325035, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710061, China
  • People's Hospital of Zhengzhou
    Zhengzhou, 450003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, 212001, China
  • Pineo Medical Ecosystem
    Tbilisi, 0114, Georgia
  • Aversi Clinic LTD
    Tbilisi, 0160, Georgia
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 01830, Korea, Republic of
  • Severance Hospital Yonsei University Health System - PPDS
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center - PPDS
    Seoul, 06351, Korea, Republic of
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 8035, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Taipei Veterans General Hospital
    Taipei City, 11217, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan City, 33305, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2022, 15 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 15 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Feb 26, 2021
StartActual
Feb 17, 2021
Primary completionActual
May 23, 2022
CompletionActual
Sep 30, 2022
Last update
Oct 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04772742
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 17, 2021
Primary completion
May 23, 2022
Completion
Sep 30, 2022
Last update
Oct 31, 2022

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion